EP1341552A2 - Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma - Google Patents

Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma

Info

Publication number
EP1341552A2
EP1341552A2 EP01975607A EP01975607A EP1341552A2 EP 1341552 A2 EP1341552 A2 EP 1341552A2 EP 01975607 A EP01975607 A EP 01975607A EP 01975607 A EP01975607 A EP 01975607A EP 1341552 A2 EP1341552 A2 EP 1341552A2
Authority
EP
European Patent Office
Prior art keywords
disease
patient
cohn fraction
immunoglobulin composition
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01975607A
Other languages
German (de)
English (en)
Inventor
Richard Weisbart
Leon E. Barstow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of EP1341552A2 publication Critical patent/EP1341552A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the treatment of immune-mediated diseases, including autoimmune diseases. More particularly, the invention relates to the treatment of rheumatoid arthritis (including polyarticular juvenile rheumatoid arthritis), Still's disease, Sjogrens Syndrome, vasculitis, including Systemic Lupus Erythmatosus , peripheral neuropathy, Raynauds Phenomenon, sensory-neural hearing loss (Meniere's Disease), fibromylagia.
  • rheumatoid arthritis including polyarticular juvenile rheumatoid arthritis
  • Still's disease Sjogrens Syndrome
  • vasculitis including Systemic Lupus Erythmatosus
  • peripheral neuropathy including Raynauds Phenomenon, sensory-neural hearing loss (Meniere's Disease), fibromylagia.
  • the invention also relates to the treatment of spondyloarthopathies including, inflammatory bowel disease (ulcerative colitis, Crohn's disease and mucinous colitis), psoriatic arthritis, Reiter.'s Syndrome and ankylosing spondylitis, temporal arteritis, polymyalgia rheumatica, agammaglobulinemia and immuno- suppressed patients.
  • spondyloarthopathies including, inflammatory bowel disease (ulcerative colitis, Crohn's disease and mucinous colitis), psoriatic arthritis, Reiter.'s Syndrome and ankylosing spondylitis, temporal arteritis, polymyalgia rheumatica, agammaglobulinemia and immuno- suppressed patients.
  • immune-mediated diseases are treated by oral administration of a pharmaceutical composition comprising Cohn Fraction II, Cohn Fraction III, or Cohn Fraction II and III.
  • the present invention relates to a method for the treatment of immune-mediated diseases by administering a pharmaceutical composition comprising human plasma fractions substantially enriched in human immunoglobulin G, for example, Cohn Fraction II + III.
  • Cohn Fraction II + III is derived from pooled human plasma and predominantly contains IgG, IgA and IgM.
  • Cohn Fraction II + III is commonly prepared according to Cohn's method 6, (Cohn E.J., et al . (1946), J. Am. Chem. Soc. 68:459-475 and W.H.O. Technical Report Series 786 (1989), incorporated herein by reference) .
  • Cohn Fraction II + III also contains albumin, alpha and beta globulins, glycine, blood clotting factors II, VII, IX and X and dextrose .
  • the microbial flora of the gastrointestinal tract is believed to have a profound influence on the development of the immune system and predisposition to develop autoimmune diseases. Contamination of the intestine with microbes is essential for the development of systemic immune tolerance to gastrointestinal antigens and the rejection of foreign organ grafts. Gaboriau- Routhiau, et al . (1996), Pediatric Res. , 39 (4) (1) : 625- 629/ Sudo, et al . (1997), J. Immunol. 159 (4) : 1739-1745.
  • the importance of microbes in the development of immune- mediated diseases is demonstrated by the relationship between exposure to microbial antigens and the development of HLA-B27 reactive arthritis in humans.
  • rheumatoid arthritis is a systemic inflammatory disease that commonly affects the joints, particularly those of the hands and feet. The onset of rheumatoid arthritis can occur slowly, ranging from a few weeks to a few months, or the condition can surface rapidly in an acute manner.
  • HLA-B27 is associated with the spondyloarthopathies . (Schwimmbeck, et al . (1988) Am. J. Med. , 85 (6A) : 51-53; Lahesma, et al . , (1991) Clin. Exp . Immunol . , 86 (3) : 399-404 ; Fielder, et al . (1995), FEBS Lett. 369 (2-3) :243-248; Erbinger, et al . (1996), Clin.
  • the classic early symptoms of adult rheumatoid arthritis include stiffness, tenderness, fever, subcutaneous nodules, achy joints, and fatigue.
  • the joints of the hands, feet, knees and wrists are most commonly affected, with eventual involvement of the hips, elbows and shoulders.
  • any type of motion becomes very painful and difficult.
  • the more severe cases of adult rheumatoid arthritis can lead to intense pain and eventual joint destruction.
  • Some 300,000 bone and joint replacement surgical procedures are performed in the U.S. annually in an effort to alleviate the pain and mobility loss resultant from arthritis related joint destruction.
  • Juvenile rheumatoid arthritis is characterized by abnormal T and B cell function and selective IgA deficiency.
  • Adult rheumatoid arthritis is a disease identified by the presence of auto-antibodies including certain characteristic rheumatoid factors.
  • the immunogenetic associations, clinical course, and functional outcome of juvenile rheumatoid arthritis are quite different from adult-onset rheumatoid arthritis.
  • rheumatoid arthritis is characterized by the presence of rheumatoid factor autoantibodies. Germ free mice genetically predisposed to produce rheumatoid factors do not produce these autoantibodies until such mice are exposed to microbes. After termination of the germ free state, rheumatoid factors are first produced by the lymphoid system of the gastrointestinal tract . Coutelier, et al . (1986) J. Immunol., 137 (1) : 337-340. These observations suggest that in some patients, rheumatoid arthritis is a reactive arthritis induced by microbial antigens in the gastrointestinal tract.
  • IgA antibodies are secreted into the intestine in response to microbial antigens. Patients with IgA deficiency have an increased incidence of autoimmune diseases, including reactive arthritis. These observations suggest that immunoglobulin secreted into the intestine protects against autoimmunity . If some individuals fail to produce antibodies that protect against the development of autoimmune diseases, then restoring normal antibodies in the intestine may ameliorate the symptoms of patients with autoimmune disease. To date, the effective treatment of autoimmune diseases such as adult rheumatoid arthritis has generally employed a combination of medication, exercise, rest and proper joint protection therapy. The therapy for a particular patient depends on the severity of the disease and the joints that are involved.
  • Aspirin is widely used for pain and to reduce inflammation.
  • non-steroidal anti- inflammatory drugs corticosteroids, gold salts, anti-malarials and systemic immuno- suppressants are widely used in moderate to advanced cases .
  • the use of steroids and immunosuppressants has significant risks and side effects both in terms of toxicity and vulnerability to potentially lethal conditions such as infection and malignancy.
  • a method of treating immune-mediated disease which does not entail the potentially adverse side effects associated with the treatments described above.
  • Superantigens have been considered as stimulants of the immune system in various autoimmune diseases including rheumatoid arthritis.
  • the gastrointestinal tract may be the site of immunologic stimulation- by superantigens . It has been considered that there may be a defect in the ability of patients with adult rheumatoid arthritis to produce antibodies with the correct neutralizing specificities.
  • One approach to treating rheumatoid arthritis is to orally administer cow's milk to patients. See U.S. Patent No.
  • Another approach to the treatment of immune- mediated diseases is tolerization of the patient suffering from the immune -mediated disease to the particular autoantigen (s) involved in the disease.
  • autoantigen s
  • multiple sclerosis patients were orally administered bovine myelin protein, which contains two multiple sclerosis autoantigens .
  • rheumatoid arthritis patients were orally administered collagen, a presumed autoantigen.
  • One drawback to tolerization is that the identification of the correct autoantigen to which tolerance is to be induced is elusive.
  • the present invention is directed to a method for treating an immune-mediated disease by orally administering a composition constituting a human plasma fraction enriched in human immunoglobulin G, ..such as, Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III and combinations thereof with or without an antacid in and amount sufficient to provide a clinically observable improvement in a patient's condition.
  • the present invention is based on the surprising discovery that the oral administration of a composition containing immunoglobulin G, optionally in conjunction with an antacid, to patients with immune -mediated disease results in a significant clinical improvement in the condition of the patient.
  • the present invention is also based on the discovery that there are no toxic effects of orally administered immunoglobulin G-enriched compositions that have been irradiated with gamma irradiation, for example.
  • the present invention provides a method for treating a patient suffering from an immune -mediated disease.
  • immune -mediated disease is meant a pathogenic disease which triggers a characteristic immune response by cells that include lymphocytes, antigen presenting cells and soluble mediators or cytokines produced by said cells.
  • An immune -mediated disease manifests in symptoms such as pain, inflammation, stiffness, hearing loss, and include such diseases as rheumatoid arthritis, Still's disease, Sjorgrens syndrome, and inflammatory bowel disease, for example.
  • the method of the present invention is employed by orally administering a human plasma fraction containing human immunoglobulin G to a subject in need of such plasma fraction.
  • a preferred human plasma fraction containing human immunoglobulin G is Cohn Fraction II.
  • Another preferred human plasma fraction containing human immunoglobulin G is Cohn Fraction III.
  • Still another preferred human plasma fraction enriched in human immunoglobulin G is Cohn Fraction II + III.
  • the human plasma fraction is administered in accordance with the present invention, optionally in conjunction with an antacid.
  • Cohn Fraction II, Cohn Fraction III, and Cohn Fraction II + III are derived from pooled human plasma and predominantly contain IgG, IgA and IgM.
  • Cohn Fraction II, Cohn Fraction III and Cohn Fraction II + III are each conventionally prepared, and are understood, in accordance with the present invention, to be pooled human immunoglobulin compositions.
  • an immunoglobulin introduced into the acidic environment of the human stomach, may suffer inactivation.
  • the human plasma fraction employed in the methods of the present invention is optionally administered in conjunction with an antacid.
  • the acid blocker may neutralize the otherwise acidic character of the gut thereby shielding the immunoglobulin from digestion in the stomach.
  • the acid- blocker and immunoglobulin may synergistically provide remediation of disease symptoms by suppressing inflammatory mediators or immune -mediated inflammation.
  • the present invention also contemplates pharmaceutical compositions comprising human plasma fractions such as, for example, Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III and combinations thereof with or without an antacid.
  • the term "pooled human immunoglobulin” refers to an immunoglobulin composition containing polyclonal antibodies obtained from the plasma of thousands of human donors.
  • the polyclonal antibodies may include IgG, IgA, IgM, etc. or fragments thereof.
  • a preferred polyclonal fraction contains IgG for treating immune -mediated diseases including rheumatoid arthritis, for example.
  • a preferred immunoglobulin composition is a preferred immunoglobulin composition,
  • Cohn Fraction II + III contains at least about 30% to about 85% IgG polyclonal antibodies, about 5% to about 30% IgA and about 1% to about 25% IgM and trace amounts of other components such as, for example, clotting factors II, VII, IX, X and alpha and beta globulins.
  • Another preferred immunoglobulin composition, Cohn Fraction II contains about 95% to about 99% IgG polyclonal antibodies, at least 0.01% to about 2% IgM and trace amounts of salt. Still another preferred immunoglobulin composition, Cohn Fraction III, contains at least about 25% IgG polyclonal antibodies, at least about 5% to about 30% IgA and about 1% to about 25% IgM, together with trace amounts of clotting factors II, VII, IX, alpha and beta globins and lipids.
  • a preferred pooled human immunoglobulin composition useful in accordance with the present invention comprises Cohn Fraction II.
  • Another preferred human immunoglobulin composition useful in accordance with the present invention comprises Cohn Fraction III.
  • Still another preferred human immunoglobulin composition useful in accordance with the present invention comprises Fraction II + III.
  • "Antacid” when used herein denotes an H 2 -blocker or acid blocker or other acid neutralizing agent which neutralizes and/or significantly reduces the acidic content of the gut.
  • a preferred antacid useful in accordance with the teachings of the present invention is cimetidine .
  • a "clinically observable improvement" when used herein refers to a significant subjective remediation of symptoms associated with the patient's immune -mediated condition.
  • subjective remediation is characterized, in accordance with the present invention as including, but not limited to, tender joint (s) , swollen joint (s) and stiffness reduction or amelioration assessments.
  • Significant subjective remediation of symptoms denotes a patient's self- assessment or a physician's assessment of stiffness, joint tenderness, swelling and the like. For example, an observable difference in swelling or tenderness in even one arthritic joint is significant-. Absence of swelling or tenderness in a previously affected joint is most significant.
  • Another aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III, optionally an antacid and a pharmaceutically acceptable carrier.
  • the composition comprises Cohn Fraction II + III and a pharmaceutically , acceptable carrier.
  • a "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer
  • wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, anti-oxidants and preservatives, can also be present.
  • coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, anti-oxidants and preservatives can also be present.
  • the patient in a preferred form of treating immune -mediated disease, is orally administered a therapeutically effective amount of Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III and combinations thereof and a pharmaceutically acceptable carrier.
  • the patient in another preferred form of treating immune-mediated disease the patient is orally administered a therapeutically effective amount of Cohn Fraction II and a pharmaceutically acceptable carrier.
  • the patient in still another preferred form of treating immune- mediated disease the patient is orally administered a therapeutically effective amount of Cohn Fraction III and a pharmaceutically acceptable carrier.
  • Treating means to ameliorate, suppress, mitigate or eliminate the clinical symptoms after the onset (i.e., clinical • manifestation) of an autoimmune disease, such as, for example, rheumatoid arthritis.
  • An effective or successful treatment provides a clinically observable improvement .
  • Oral administration as used herein includes oral, enteral or intragastric administration.
  • “In conjunction with” as used herein means before, substantially simultaneously with or after oral administration of antacid.
  • the administration of a composition such as, for example, Cohn Fraction II + III can not precede or follow administration of an antacid by so long an interval of time that the relevant effects of the substance administered first have expired. Therefore, the immunoglobulin composition should usually be administered within a therapeutically effective time.
  • therapeutically effective time is meant a time frame in which the antacid or immunoglobulin composition (e.g., Cohn Fraction II + III or Cohn Fraction II) is still active within the patient.
  • the immunoglobulin composition i.e., Cohn Fraction II, Cohn Fraction III and Cohn Fraction II + III
  • cold alcohol e.g., ethanol
  • an antacid is optionally administered in conjunction with the Cohn Fraction II, Cohn Fraction III, and/or Cohn Fraction II + Ill composition.
  • the immunoglobulin composition and the antacid are administered simultaneously in a unitary pharmaceutical composition.
  • the immunoglobulin composition is administered at a therapeutically effective time after administration of the antacid.
  • the antacid is aluminum hydroxide or magnesium hydroxide such as Maalox®, Mylanta® or Tagamet® which are available commercially.
  • the antacid is an H2 blocker, such as
  • Cimetidine or Ranitidine Cimetidine or Ranitidine.
  • the dosage of antacid administered in conjunction with the immunoglobulin composition depends on the particular H 2 -blocker used.
  • the antacid is Mylanta®, between 15 ml and 30 ml is preferred. Most preferably the dosage of Mylanta® is 15 ml.
  • the preferred dosage is between 400 and 800 mg per day.
  • the dosage of the immunoglobulin compositions of the present invention administered to the patient may be varied depending upon severity of the patient's condition and other clinical factors. Preferably, the dosage will be as small as possible while still providing a clinically observable and therapeutically effective result.
  • the most preferable and therapeutically effective doses are those that have the largest effect in terms of alleviating the patient's disease condition; including pain.
  • Therapeutically effective dosages of the Cohn Fraction II, Cohn. Fraction III and/or Cohn Fraction II + III composition may range from as little as 5 mg/kg up to as much as 5 g/kg per day.
  • appropriate doses of the compositions of the present invention are about 5 mg/kg body weight to about 30 mg/kg body weight per day.
  • the preferred dose is given in increments, it may also be given as a single dose.
  • the dose of the immunoglobulin composition may be administered at any time during the day, it is preferred that it be administered in the morning, prior to substantial patient activity.
  • the patient's arthritic condition can be determined, for example, by the patient's self-assessment of his or her pain, stiffness, etc. Another way to determine the patient's arthritic condition is. for a physician to examine a patient's joint tenderness and swelling.
  • a decided practical advantage of the present invention is that the composition containing a human plasma fraction enriched in human immunoglobulin G, such as, for example, Cohn Fraction II + III, may be administered in a convenient . manner such as by the oral route, although the invention also contemplates administering of the claimed compositions by intravenous, aerosol or suppository routes . Oral administration is most preferred.
  • the active ingredients which comprise the requisite immunoglobulin composition i.e., Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III
  • the active ingredients which comprise the requisite immunoglobulin composition i.e., Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III
  • compositions can be coated by, or administered with, a material to prevent inactivation.
  • a material to prevent inactivation for example, an enteric coated composition can be specifically designed to transport Cohn Fraction II + III to the gastrointestinal tract.
  • Enteric coating technology is conventional in the art of pharmaceutical preparation and is readily practiced in accordance with the present invention with the knowledge of the ordinarily skilled artisan.
  • the active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets designed to pass through the stomach (i.e., enteric coated) , or it may be incorporated directly with the food of the diet.
  • Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • the tablets, troches, pills, capsules, and the like, as described above, may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil or wintergreen or cherry flavoring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid, and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or a
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • Cohn Fraction II, Cohn Fraction III and/or Cohn Fraction II + III may be incorporated into sustained-release preparations and formulations.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subjects to be treated, each unit containing a predetermined quantity of Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III with or without an antacid, calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the requirements for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the immunoglobulin composition chosen, the antacid and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an immunoglobulin fraction for the treatment of autoimmune disease herein disclosed in detail.
  • the immunoglobulin composition with or without an antacid is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore described.
  • a unit dosage form can, for example, contain the Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III in amounts ranging from about 5 mg/kg to about 5 g/kg and, if desired, an antacid such as cimetidine in an amount ranging from about 200 to about
  • Clinically observable results from the administration of Cohn Fraction II, Cohn Fraction III or Cohn Fraction II + III in conjunction with antacid may be observed immediately or as early as in 2 weeks. However, it may take up to 6 weeks or more to obtain a measurable benefit. Initial dose levels used during the first few weeks of treatment may be reduced once clinical improvement has been observed. Reductions in dose levels of up to 90% may be made after the first few weeks.
  • the immunoglobulin composition is terminally sterilized. Specifically, a human plasma fraction such as Cohn Fraction II + III is exposed to controlled gamma irradiation at a rate sufficient to sterilize Cohn Fraction II + III for therapeutic use.
  • Exposure is at a rate of about 2 to about 3 KGy per hour for a total dose of about 20 to about 50 KGy.
  • Gamma irradiation is applied to capsules containing Cohn Fraction II + III precipitate to destroy or otherwise inactivate inherent viral and bacterial contaminants .
  • Irradiating Cohn Fraction II + III capsules for a total dose of about 25 to about 50 KGy ensures a Sterility Assurance Level (SAL) of about 10 "s and does not destabilize the immunoglobulin composition contained therein.
  • SAL Sterility Assurance Level
  • the human plasma immunoglobulin composition is terminally sterilized by heat to destroy or otherwise inactivate inherent viral and bacterial contaminants.
  • Heat sterilization for example moist heat sterilization, is conventionally employed by directly contacting the composition of the immunoglobulin composition with saturated steam at temperatures ranging from about 150°C to about 350°C and at pressures up to 5 bar.
  • heat sterilization is conventionally implemented in accordance with the present invention.
  • the oral treatment method in accordance with the present invention may be used to treat rheumatoid arthritis (including juvenile polyarticular rheumatoid arthritis) and other related immune-mediated diseases such as Still's disease, Sjogrens Syndrome, vasculitis, including Systemic Lupus Erythmatosus (SLE) , peripheral neuropathy, Raynauds Phenomenon, sensory-neural hearing loss (Meniere's Disease) , fibromylagia, spondyloarthopathies including, inflammatory bowel disease (ulcerative colitis, Crohn's disease and mucinous colitis), psoriatic arthritis, Reiter's Syndrome and ankylosing spondylitis, temporal arteritis, polymyalgia rheumatica and agammaglobulinemia.
  • the treatment of spondyloarthopathies according to the present invention is contemplated to employ the same dosages as for rheumatoid arthritis, and
  • Fraction I precipitate
  • the supernatant was cooled to -5°C and the pH was adjusted to 6.7 to 6.9 with citric acid. More cold ethanol was added to reach a final concentration of 25% (vol . /vol . ) . This ethanol concentration maximized the recovery of IgG, IgA and IgM and also included amounts of albumin, alpha and beta globulins in the resulting
  • Fraction II + III precipitate which was collected by centrifugation.
  • the Fraction II + III precipitate was suspended in 0°C-5°C water-for-injection (WFI) , containing 1% glycine and 2% dextrose (final concentrations) .
  • the pH was adjusted to 6.0 with 0.1 M citric acid.
  • the protein concentration of the Fraction II + III solution was 2.5
  • Fraction II + III solution (0-10°C) was placed in containers at a solution layer depth of 0.70 0.2 inch. The solution was then freeze-dried and stored in sealed plastic containers at 1 to 10°C.
  • Lyophilized Fraction II + III powder in sealed plastic containers was exposed to controlled gamma irradiation. Exposure was 2-3KGy per hour for a total of 25 to 50 KGy.
  • Fraction II + III precipitate prepared as set forth in Example 1, is dissolved in sufficient water-for- injection at -5°C to give a 1% protein concentration.
  • the pH is adjusted to 7.2 and cold ethanol is added to reach a final concentration of 20% to 25 ⁇ (vol . /vol . ) .
  • Fraction II is removed from the filtrate by centrifugation. (See Oncley et al . (1949), J. Am. Chem. Soc . , 71:541-550, incorporated herein by reference) .
  • the supernatant produced contains Fraction
  • Fraction II and/or Fraction III is redissolved in water suitable for injection to give a solution that is 1% to 5% protein and about 15% glycine.
  • the product is then lyophilized by freezing for about 4 hours at a temperature of -30°C to -35°C.
  • the shelf temperature is increased from -30°C to -10°C for 2 hours.
  • the shelf temperature is then increased to 0°C.
  • the primary drying is done at 0°C or until the thermocouples are at 0°C (about 20 hours from start of cycle) .
  • the secondary cycle is conducted at 30°C shelf temperature for about 6 hours .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pour traiter des patients souffrant d'une des très nombreuses maladies d'origine immunitaire, y compris l'arthrite rhumatoïde, on peut administrer à ces deniers, par voie orale, des fractions de plasma humain sensiblement enrichies en immunoglobuline humaine G, telle que la fraction Cohn II + III et facultativement un antiacide. L'administration par voie orale de la fraction Cohn II + III produit une amélioration clinique significative du degré de l'activité de la maladie chez les patients souffrant d'arthrite rhumatoïde par exemple.
EP01975607A 2000-09-28 2001-09-28 Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma Withdrawn EP1341552A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US672911 1984-11-19
US23625500P 2000-09-28 2000-09-28
US67291100A 2000-09-28 2000-09-28
US236255P 2000-09-28
PCT/US2001/030610 WO2002026258A2 (fr) 2000-09-28 2001-09-28 Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma enrichies en immunoglobuline g

Publications (1)

Publication Number Publication Date
EP1341552A2 true EP1341552A2 (fr) 2003-09-10

Family

ID=26929598

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01975607A Withdrawn EP1341552A2 (fr) 2000-09-28 2001-09-28 Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma

Country Status (4)

Country Link
EP (1) EP1341552A2 (fr)
JP (1) JP2004525077A (fr)
CA (1) CA2423805A1 (fr)
WO (1) WO2002026258A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2437099A1 (fr) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Procedes et compositions destines au traitement de dysfonctions immunitaires

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448344B (sv) * 1978-02-06 1987-02-16 Stolle Res & Dev Antikropp for behandling av reumatoid artrit samt sett att framstella denna
DE3272680D1 (en) * 1981-05-01 1986-09-25 Miles Lab Oral pharmaceutical composition containing immune globulin
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
DK0744957T3 (da) * 1994-02-18 2000-03-06 Immuno Ag Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
DE4424935C1 (de) * 1994-07-14 1996-03-21 Immuno Ag Humanes virussicheres monomeres Immunglobulin A und Verfahren zu seiner Herstellung
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0226258A2 *

Also Published As

Publication number Publication date
WO2002026258A2 (fr) 2002-04-04
WO2002026258A3 (fr) 2002-10-24
CA2423805A1 (fr) 2002-04-04
JP2004525077A (ja) 2004-08-19

Similar Documents

Publication Publication Date Title
US10912955B2 (en) Treatment of celiac disease, C. difficile infection, food intolerance and food allergy with secretory IgA/IgM
US20080145420A1 (en) HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US7597891B2 (en) Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
CA2462682A1 (fr) Utilisation de gammaglobuline pour le traitement de maladies d&#39;origine immunologique
US7794721B2 (en) Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US20020098182A1 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
CA2249448C (fr) Composition anti-inflammatoire a base d&#39;oeufs, technique d&#39;isolation et usage
HUT62486A (en) Process for producing pharmaceutical compositions comprising antigene-antibody complexes
WO1998047529A1 (fr) Combinaisons d&#39;antigene et de composant de liaison propre aux muqueuses, utilisees pour l&#39;induction d&#39;une tolerance immunitaire specifique
CA2317813A1 (fr) Composition et methode de traitement et de prevention de l&#39;arthrite et/ou de maladies auto-immunes
US6090380A (en) Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
WO1999002188A1 (fr) Anticorps de jaune d&#39;oeuf de poule, diriges contre les antigenes de clostridium difficile et leur utilisation dans le traitement de la colite pseudomembraneuse
WO2002026258A2 (fr) Traitement des maladies d&#39;origine immunologique au moyen de l&#39;administration par voie orale de fractions de plasma enrichies en immunoglobuline g
US20040180045A1 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
WO2002022079A2 (fr) Procede de preparation d&#39;immunoglobuline et utilisations de cette derniere
South et al. The IgA antibody system
Golding Is there an allergic synovitis?
WO2000043019A2 (fr) Composition anti-inflammatoire a base d&#39;oeuf et methode de traitement et de prevention de l&#39;inflammation
CA2370268A1 (fr) Traitement de la polyarthrite rhumatoide de l&#39;adulte par l&#39;administration orale d&#39;immunoglobuline humaine provenant d&#39;un pool de donneurs et d&#39;un antiacide
US11319361B2 (en) Treatment of intestinal dysbiosis with immunoglobin
JPH07138187A (ja) 経口免疫寛容原、経口慢性関節リウマチ治療剤及び機能性食品
JP2001502309A (ja) 溶血性尿毒性症候群を予防するための経口投与薬剤を製造するために免疫グロブリン製剤を使用する方法
JPH09241166A (ja) Ｈｓｐ６０ファミリーに属するタンパク質のジンセノサイド類含有合成抑制剤
JPH09194353A (ja) Ｈｓｐ６０ファミリーに属するタンパク質のジンゲロール含有合成抑制剤
BOESMAN-FINKELSTEIN et al. Bovine lactogenic immunity: a concept whose time has come (?)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030325

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20070212